Lista de obras -

A review of the venous thrombotic issues associated with multiple myeloma

artículo científico publicado en 2016

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

artículo científico publicado en 2017

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

scientific article published on 03 November 2020

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

scientific article published on 03 April 2020

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

artículo científico publicado en 2020

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

artículo científico publicado en 2019

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

artículo científico publicado en 2020

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

scientific article published on 23 August 2020

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma

scientific article published on 04 November 2020

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

artículo científico publicado en 2018

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

artículo científico publicado en 2018

Emerging drugs for the treatment of Waldenström macroglobulinemia

scientific article published on 21 September 2020

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

artículo científico publicado en 2018

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

artículo científico publicado en 2018

Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications

artículo científico publicado en 2020

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

artículo científico publicado en 2020

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re

artículo científico publicado en 2018

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

artículo científico publicado en 2020

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

artículo científico publicado en 2019

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

artículo científico publicado en 2017

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

artículo científico publicado en 2020

Screening for Gaucher disease among patients with plasma cell dyscrasias

artículo científico publicado en 2019

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

scientific article published on 25 September 2020

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

artículo científico publicado en 2017

The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia

scientific article published on 13 July 2020

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

artículo científico publicado en 2020

Lista de obras de

A review of the venous thrombotic issues associated with multiple myeloma

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

Emerging drugs for the treatment of Waldenström macroglobulinemia

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

Screening for Gaucher disease among patients with plasma cell dyscrasias

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis